SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Technology Stocks : John, Mike & Tom's Wild World of Stocks
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: wlheatmoon who wrote (1197)6/3/2000 8:00:00 AM
From: accountclosed  Read Replies (3) of 2850
 
Friday June 2, 7:11 pm Eastern Time
Genentech says FDA okays heart attack drug
SOUTH SAN FRANCISCO, Calif., June 2 (Reuters) - Biotechnology company Genentech Inc. (NYSE:DNA - news) on Friday said the U.S. Food and Drug Administration (FDA) has approved its product called TNKase, also known as Tenecteplase, for use in treating heart attack victims.

TNKase is a single-bolus thrombolytic agent that helps open clogged arteries that have led to a heart attack, Genentech said, adding that it can be administered in just over five seconds, more quickly than any other drug of its kind.

Genentech shares closed up 2-1/4 at $110 on the New York Stock Exchange. The company announced the FDA approval after the market closed.


biz.yahoo.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News